National Institutes of Biotechnology Malaysia (NIBM) is a consortium of three national biotechnology institutes – Malaysian Institute of Pharmaceuticals & Nutraceuticals (IPharm) in Gelugor, Penang, Agro-Biotechnology Institute Malaysia (ABI) in Serdang, Selangor and Malaysia Genome & Vaccine Institute (MGVI) in Bangi, Selangor, established on 27 January 2012 as a Company Limited by Guarantee (CLBG), an autonomous not-for-profit entity to administer IPharm, ABI and MGVI.
NIBM focuses on demand-driven research, encompassing fundamental, applied, and experimental development research. It also provides scientific services and consultation, alongside technology transfer, product development, and formulation.
IPharm focuses on drug discovery from natural tropical sources for healthcare, pharmaceuticals, and nutraceuticals. ABI concentrates on the discovery and development of value-added crops, livestock, and food products to enhance quality. MGVI emphasizes cutting-edge research in focused on genome, omics and human vaccine development.
For more information, visit www.nibm.my